Pharmacology of antidepressants

Journal of Clinical Psychopharmacology

Volumn 17, Issue 2 SUPPL. 1, 1997, Pages

  Frazer, Alan ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0030909059     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199704001-00002     Document Type: Conference Paper

References (158)

1. Keith SJ, Matthews SM. The value of psychiatric treatment: its efficacy in severe mental disorders. Psychopharmacol Bull 1993; 29:427-30.
2. Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55[9, suppl A]:34-9.
3. Prange AJ Jr. The pharmacology and biochemistry of depression. Dis Nerv Syst 1964;25:217-21.
4. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122:509-22.
5. Coppen A. The biochemistry of affective disorders Br J Psychiatry 1967;113:1237-64.
6. Lapin IP, Oxenkrug GF. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet 1969;1:132-6.
7. Carlsson A, Corrodi H, Fuxe K, Hökfelt T. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-a-ethyl-meta-tyramine. Eur J Pharmacol 1969;5:357-66.
8. Bowden CL, Koslow SH, Hanin I, Maas JW, Davies JM, Robins E. Effects of amitriptyline and imipramine on brain amine neurotransmitter metabolites in cerebrospinal fluid. Clin Pharmacol Ther 1985;37:316-24.
9. Garattini S, De Gaetano G, Samanin R, Bernasconi S, Roncaglioni MC. Effects of trazodone on serotonin in the brain and platelets of the rat. Biochem Pharmacol 1976;25:13-6.
10. 14C]S-hydroxytryptamine uptake by rat platelets. J Pharm Pharmacol 1977;29:546-9.
11. Ascher JA, Cole JO, Colin J-N, Feigner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
12. Golden RN, Rudorfer MV, Sherer MA, Linnoila M, Potter WZ. Bupropion in depression, I: biochemical effects and clinical response. Arch Gen Psychiatry 1988;45:139-43.
13. Golden RN, DeVane CL, Laizure SC, Rudorfer MV, Sherer MA, Bupropion in depression, II: the role of metabolites in clinical outcome. Arch Gen Psychiatry 1988;45:145-49.
14. Perumal AS, Smith TM, Suckow RF, Cooper TB. Effects of plasma from patients containing bupropion and its metabolites on the uptake of norepinephrine. Neuropharmacology 1986;25:199-202.
15. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33:811-9.
16. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47:411-8.
17. Delgado PL, Price LH, Miller HL. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991;27:321-30.
18. Moja EA, Cipollo P, Castoldi D, Toffaneti O. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sci 1989;44:971-6.
19. Miller HL, Delgado PF, Salomon RM, Langlois R. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 1996; 53:117-28.
20. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995; 56[6, suppl]:3-11.
21. Hemrick-Luecke SK, Snoddy HD, Fuller RW. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 1994;55:479-83.
22. Fuller RW, Snoddy HD, Cohen ML. Interactions of trazodone with serotonin neurons and receptors. Neuropharmacology 1984;23: 539-44.
23. Salazar DE, Chaikin PC, Swanson BN, Raymond RH. The effects of nefazodone and fluoxetine on platelet serotonin-uptake and whole blood serotonin. Clin Pharmacol Ther 1994;55:137.
24. Maj J, Palider W, Rawlow A. Trazodone. a central serotonin antagonist and agonist. J Neural Transm 1979;44:237-48.
25. Clements-Jewery S, Robson PA, Chidley LJ. Biochemical investigations into the mode of action of trazodone. Neuropharmacology 1980;19:1165-73.
26. 2-selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995;10[suppl 2]:S107-18.
27. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 1980;210:88-90.
28. Enna SJ, Kendall DA. Interaction of antidepressants and brain neurotransmitter receptors. J Clin Psychopharmacol 1981; 1[suppl]:12S-16S.
29. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-5.
30. 2A receptors after chronic treatment with Remeron. Eur Neuropsychopharmacol 1995;5:306.
31. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-6.
32. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7[suppl]:24S-35S.
33. Cusack B, Nelson A, Eichelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-65.
34. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993;54[9, suppl]: 14-34.
35. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacology 1996;16:19-25.
36. VanderMaelen CP, Braselton JP. Acute administration of the antidepressant trazodone increases noradrenergic locus coeruleus neuronal firing in rats. Arch Int Pharmacodyn Ther 1990;308: 13-20.
37. Hauser K, Olpe H-R, Jones RSG. Trimipramine, a tncyclic antidepressant exerting atypical actions on the central noradrenergic system. Eur J Pharmacol 1985;111:23-30.
38. de Boer Th, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-AZA-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 1988;27:399-408.
39. 2-adrenoceptor antagonists mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996;277:852-60.
40. 2-adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1996;277:861-71.
41. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980;19:355-63.
42. 2 adrenergic heteroreceptors of 5-hydroxytryptamine terminals in the rat hippocampus. NS Arch Pharmacol 1993;347:266-72.
43. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52[6, suppl]:4-10.
44. de Montigny C, Aghajanian GK. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 1978;202:1303-6.
45. Pickel VM, Joh TH, Chan J, Beaudet A. Serotonergic terminals: ultrastructure and synaptic interaction with catecholamine-containing neurons in the medial nuclei of the solitary tracts. J Comp Neurol 1984;225:291-301.
46. Segal M. Serotonergic innervation of the locus coeruleus from the dorsal raphe and its actions on responses to noxious stimuli. J Physiol 1979;286:401-15.
47. Aston-Jones G, Akaoka H, Charlety P, Chouvet G. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J Neurosci 1991;11:760-9.
48. Shiekhattar R, Aston-Jones G. Sensory responsiveness of brain noradrenergic neurons is modulated by endogenous brain serotonin. Brain Res 1993;623:72-76.
49. Ennis M, Aston-Jones G. Activation of locus coeruleus from nucleus paragigantocelularis: a new excitatory amino acid pathway in brain. J Neurosci 1988;8:36644-3657.
50. 1A receptors to selectively attenuate glutamate-evoked responses of locus coeruleus neurons. Society for Neuroscience 1990;16:799.
51. 2 agonist augments Á-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience 1993;54: 409-20.
52. 1251-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments. J Pharmacol Exp Ther 1991;257:681-90.
53. 1A receptor regulation. Effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropyschopharmacology 1991;4:131-44.
54. 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 1994;10: 41-51.
55. Kuhn R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 1958;115:459-64.
56. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 1993;150: 571-7.
57. Klerman GL, Cole JO. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965;17: 101-41.
58. Klein DF, Gittelman R, Quitkin F, Rifkin A. Diagnosis and drug treatment of psychiatric disorders. 2nd ed. Baltimore: Williams & Wilkins, 1980.
59. Brotman AW, Falk WE. Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1031-40.
60. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wagner SG, Ocepek-Welikson K, Nunes E, Rabkin JG, Klein DF. Atypical depression, panic attacks, and response to imipramine and phenelzine. Arch Gen Psychiatry 1990;47:935-41.
61. Kocsis JH, Croughan JL, Katz MM, Butler TP, Secunda S, Bowden Cl, Davies JM. Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 1990;147: 621-4.
62. Kline NS. Clinical experience with iproniazid. J Clin Exp Psychopathol 1958;19[suppl]:72-8.
63. Crane GE. Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatr Res Rep 1959;8:142-52.
64. Shih JC. Molecular basis of human MAO A and B. Neuropsychopharmacology 1991;4:17.
65. Murphy DL, Aulakh CS, Garrick NA. Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987.
66. Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. Arch Gen Psychiatry 1989;46:435-50.
67. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12: 185-219
68. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PH, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz D, Klein DF. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-39.
69. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, Rabkin JG, Wager SG, Nunes E, Klein DF. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 1991;48:319-23.
70. Nolen WA, Haffmans J. Treatment resistant depression. Review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants. Int Clin Psychopharmacol 1989;4:217-28.
71. Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11.
72. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM, Klein DF. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118-23.
73. Workman EA, Short DD. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry 1993;54:5-12.
74. Kinney JL, Evans RL Jr. Evaluation of amoxapine. Clin Pharm 1982;1:417-24.
75. Gruter W, Poldinger W. Maprotiline. Mod Probl Pharmacopsychiatry 1982;18:17-18.
76. Stern WL, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry 1983;44[5, part 2]:148-52.
77. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990;51:9-12.
78. Kasper S, Fuger J, Moller H-J. Comparative efficacy of antidepressants. Drugs 1992;43[suppl 2]:11-23.
79. Dechant KL, Clissold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225-53.
80. Grimsley SR, Jam MW. Paroxetine, sertraline, and fluoxetine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11:930-57.
81. Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992; 44:604-24.
82. Montgomery SA. Selective serotonin reuptake inhibitors in the acute treatment of depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995:1043-51.
83. Guelfl JD, White C, Magni G. A randomized, double-blind comparison of venlafaxine and placebo in inpatients with major depression and melancholia Clin Pharmacol 1992;15[1, suppl, pt B]:323B.
84. Schweizer E, Feighner J, Mandos L, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8.
85. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fisher DE, Hearst E. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
86. Clerc GE, Ruimy P, Verdeau-Pailläs J on behalf of the Venlafaxine French Inpatient Study Group. A double blind-comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9: 139-43.
87. Rickels K, Robinson DS, Schweizer E, Marcus RN, Roberts DL. Nefazodone: aspects of efficacy. J Clin Psychiatry 1995;56[6, suppl]:43-6.
88. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs 1995;4[suppl 1]:39-48.
89. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995; 34:165-71.
90. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 1995;10:173-80.
91. Richou H, Ruimy P, Charbaut J, Delisle JP, Brunner H, Patris M, Zivkov M. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995;10:263-71.
92. van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, Mendlewicz J. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10:3-9.
93. Frazer A, Conway P. Pharmacologic mechanisms of action of antidepressants. Psychiatr Clin North Am 1984;7:575-86.
94. de Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry 1990;51[B, suppl]:4-8.
95. 3H]-Cyclic AMP production in slices of rat cerebral cortex. Neuropharmacology 1974;13:1131-40.
96. Vetulani J, Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 1975;257:495-6.
97. Banerjee SP, Kung LS, Chanda SK. Development of β adrenergic receptor subsensitivity by antidepressants. Nature 1977;268: 455-6.
98. Aghajanian GK. Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. In: Youdim MBH, Lovenberg W, Sharman DF, Lagnado JR, eds. Essays in neurochemistry and neuropharmacology, vol 3. New York: John Wiley, 1978:1-33.
99. Sulser F. Functional aspects of the norepinephrine receptor coupled adenylate cyclase system in the limbic forebrain and its modification by drugs which precipitate or alleviate depression: molecular approaches to an understanding of affective disorders. Pharmakopsychiatr Neuropsychopharmakol 1978;11:43-52.
100. de Montigny C, Cournoyer G, Morissette R, Langlois R. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327-34.
101. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51.
102. George MS, Lydiard RB. Speed of onset of action of the newer anti-depressants - fluoxetine and bupropion. Int Clin Psychopharmacol 1991;6:209-17.
103. Burke MJ, Preskorn SH. Short-term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation progress. New York: Raven Press, 1995:1053-65.
104. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
105. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
106. Bech P, Allerup P, Gram LF, Reisby DH, Rosenberg R, Jacobsen O, Nagy A. The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981;63:290-9.
107. Khan A, Cohen S, Dager S, Avery DH, Dunner DL. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Disord 1989;17:33-8.
108. Prien RF, Blaine JD, Levine J. Antidepressant drug therapy: the role of the new antidepressants. Hosp Community Psychiatry 1985;36:513-6.
109. Rickels K, Derivan A, Entsuah R, Miska S, Rudolph R. Rapid onset of antidepressant activity with venlafaxine treatment. Depression 1995;3:146-53.
110. Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994;9:245-50.
111. Kasper S. Clinical efficacy of mirtazapine: a review of metaanalyses of pooled data. Int Clin Psychopharmacol 1995; 10[suppl 4]:25-37.
112. Lader M, Lang RA, Wilson GD. Patterns of improvement of depressed in-patients. In: Maudsley Monograph No. 30, Oxford Small IF. New York: Oxford University Press, 1987.
113. Small JG, Milstein V, Kellams JJ. Comparative onset of improvement in depressive symptomatology with drug treatment electroconvulsive therapy, and placebo. J Clin Psychopharmacol 1981;1]suppl 6[:62S-69S.
114. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993;3:127-35.
115. Katz MM, Koslow SH, Maas JW, Frazer A, Bowden CL, Casper R, Croughan J, Kocsis J, Redmond E Jr. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987;17:297-309.
116. Tollefson GD. Antidepressant treatment and side effect considerations. J Clin Psychiatry 1991;52:S4-13.
117. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992;52:61-6.
118. Aston Jones G, Chiang C, Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res 1991;88:501-20.
119. Salazar DE, Dockens RC, Milbrath RL, Raymond RH, Fulmor IE, Chaikin PC, Uderman HD. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35:730-8.
120. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10[suppl 4]:37-45.
121. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med 1989;19[suppl 16]:1-40.
122. Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clin Pharm 1982;1:406-17.
123. Rudolph RL, Derivan A. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16[suppl 2]:54S-61S.
124. Roose SP, Classman AH, Giardina EG, Johnson LL, Walsh BT, Bigger JT Jr. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987;7:247-51.
125. Cole JO, Brodkin JA. Affective drug side effects. J Clin Psychiatry 1990;51:S21-6.
126. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988; 26:265-71.
127. Harto-Traux N, Stern WC, Miller LL. Effects of bupropion on body weight. J Clin Psychiatry 1983;44:183-6.
128. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994;10:18-46.
129. Skowron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992;12:18-22.
130. Krijzer F, Snelder M, Bradford D. Comparison of the (pro)conclusive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model. Neuropsychobiology 1984;12:249-54.
131. Wagner W, Plekkenpol B, Gray TE, Vlaskamp II, Essers H. Review of fluvoxamine safety database. Drugs 1992;43[suppl 2]:48-54.
132. Preskorn S, Fast G. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52[6, suppl]:23-33.
133. Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry 1992;53:443-6.
134. Sachs GS, Lafer B, Stoll AL, Banov M, Thibauld AB, Tohen M, Rosenbaum JF. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-3.
135. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56[6, suppl]:12-21.
136. Davidson JRT. Sexual dysfunction and antidepressants. Depression 1994/1995;2:233-40.
137. Segraves RT. Overview of sexual dysfunction complicating the treatment of depression. J Clin Psychiatry Monograph 1992; 19:4-10.
138. Gardner EA, Johnston JA. Bupropion - an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985;5:24-9.
139. Sher M, Krieger NJ, Juergens S. Trazodone and priapism. Am J Psychiatry 1983;140:1362-3.
140. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. J Clin Psychiatry 1987;48:244-5.
141. Jue SG, Dawson GW, Brogden RN. Amoxapine: a review of its pharmacology and efficacy in depressed states. Drugs 1982; 24:1-23.
142. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268:3441-5.
143. Montgomery SA. Suicide and antidepressants. Drugs 1992; 43:24-31.
144. Crome P, Newman B. Fatal tricyclic antidepressant poisoning. J R Soc Med 1979;72:649-53.
145. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. BMJ 1987;295:1021-4.
146. de Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992;43[suppl 2]:40-6.
147. Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet 1963;ii:849-51.
148. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry 1989;155[suppl 6]:38-45.
149. Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm 1988;26:S31-56.
150. Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: a re-examination. Can J Psychiatry 1984;29:707-11.
151. Hill S, Yau K, Whitwam J. MAOIs to RIMAs in anesthesia - a literature review. Psychopharmacology 1992;106:843-5.
152. Meredith TJ, Vale JA. Poisoning due to psychotropic agents. Adverse Drug React Acute Poisoning Rev 1985;4:83-126.
153. Linden CH, Rumack BH, Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med 1984;13:1137-44.
154. Van Wyck, Fleet J, Manberg PJ, Miller LL, Harto-Truax N, Sato T, Fleck BJ, Stern WJ, Cato AE. Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry 1983;44:191-6.
155. Spiller HA, Ramoska EA, Krenzelok EP, Sheen SR, Borys DJ, Villalobos D, Muir S, Jones-Easom L. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med 1994;12: 43-5.
156. Hoes MJAJM, Zijpveld JHB. First report of mirtazapine overdose, Int Clin Psychopharmacol 1996;11:147.
157. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-9.
158. Richelson E, Nelson A Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984;230:94-102.